Commonwealth Equity Services acquired a new position in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The hedge fund acquired 30,022 shares of the specialty pharmaceutical company’s stock, valued at approximately $906,000. Commonwealth Equity Services owned approximately 0.09% of AMAG Pharmaceuticals as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. ICON Advisers bought a new stake in shares of AMAG Pharmaceuticals during the third quarter worth $378,000. KBC Group bought a new stake in shares of AMAG Pharmaceuticals during the third quarter worth $1,545,000. Gerstein Fisher bought a new stake in shares of AMAG Pharmaceuticals during the third quarter worth $1,713,000. HealthInvest Partners bought a new stake in shares of AMAG Pharmaceuticals during the fourth quarter worth $15,699,000. Finally, Janus Capital Management boosted its stake in shares of AMAG Pharmaceuticals by 140.9% in the third quarter. Janus Capital Management now owns 1,815,023 shares of the specialty pharmaceutical company’s stock worth $72,111,000 after buying an additional 1,061,551 shares during the period.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at 22.18 on Thursday. The stock has a 50 day moving average price of $26.40 and a 200 day moving average price of $43.18. AMAG Pharmaceuticals, Inc. has a 52 week low of $21.69 and a 52 week high of $77.73. The stock has a market capitalization of $769.71 million and a PE ratio of 4.56.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Tuesday, November 3rd. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.21 by $0.19. During the same period in the previous year, the firm earned $0.06 earnings per share. The firm earned $103.50 million during the quarter, compared to analyst estimates of $113.88 million. The company’s quarterly revenue was up 340.4% on a year-over-year basis. Equities analysts forecast that AMAG Pharmaceuticals, Inc. will post $4.44 EPS for the current year.

A number of research firms have commented on AMAG. Jefferies Group reiterated a “buy” rating and issued a $70.00 price target (up from $28.95) on shares of AMAG Pharmaceuticals in a research note on Thursday, November 12th. Deutsche Bank decreased their price target on AMAG Pharmaceuticals from $43.00 to $42.00 and set a “hold” rating for the company in a research note on Thursday, January 14th. TheStreet cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 3rd. Zacks Investment Research cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 4th. Finally, Barclays began coverage on AMAG Pharmaceuticals in a research note on Thursday, January 21st. They issued an “equal weight” rating and a $32.00 price target for the company. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. AMAG Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $57.38.

In related news, Director John A. Fallon bought 3,230 shares of the stock in a transaction that occurred on Tuesday, November 10th. The stock was purchased at an average cost of $31.20 per share, with a total value of $100,776.00. Following the purchase, the director now directly owns 6,086 shares of the company’s stock, valued at approximately $189,883.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (NASDAQ:AMAG), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

12 Month Chart for NASDAQ:AMAG

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.